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Abstract: Ischemic stroke is categorized by either permanent or transient blood flow obstruction,
impeding the distribution of oxygen and essential nutrients to the brain. In this study, we examined
the neuroprotective effects of compound A3, a synthetic polyphenolic drug product, against ischemic
brain injury by employing an animal model of permanent middle cerebral artery occlusion (p-MCAO).
Ischemic stroke induced significant elevation in the levels of reactive oxygen species and, ultimately,
provoked inflammatory cascade. Here, we demonstrated that A3 upregulated the endogenous
antioxidant enzymes, such as glutathione s-transferase (GST), glutathione (GSH), and reversed
the ischemic-stroke-induced nitric oxide (NO) and lipid peroxidation (LPO) elevation in the
peri-infarct cortical and striatal tissue, through the activation of endogenous antioxidant nuclear factor
E2-related factor or nuclear factor erythroid 2 (Nrf2). In addition, A3 attenuated neuroinflammatory
markers such as ionized calcium-binding adapter molecule-1 (Iba-1), cyclooxygenase-2 (COX-2),
tumor necrotic factor-α (TNF-α), toll-like receptors (TLR4), and nuclear factor-κB (NF-κB) by
down-regulating p-JNK as evidenced by immunohistochemical results. Moreover, treatment with A3
reduced the infarction area and neurobehavioral deficits. We employed ATRA to antagonize Nrf2,
which abrogated the neuroprotective effects of A3 to further assess the possible involvement of the
Nrf2 pathway, as demonstrated by increased infarction and hyperexpression of inflammatory markers.
Together, our findings suggested that A3 could activate Nrf2, which in turn regulates the downstream
antioxidants, eventually mitigating MCAO-induced neuroinflammation and neurodegeneration.
Keywords: A3; middle cerebral artery occlusion; all-trans retinoic acid; neurodegeneration;
antioxidant system

1. Introduction
Stroke is the most prominent cause of human disability and it might either be classified as transient
or permanent, and it occurs as a result of occlusion in an artery irrigating the brain. Ischemic stroke
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has an 80% higher incidence as compared to other types of stroke and the middle cerebral artery
(MCA) is the most common place for the occurrence of an ischemic stroke [1]. The prevention
and treatment of stroke are of utmost importance with numerous medications under investigation.
However, until now, no treatment strategy has proved to be effective by controlled clinical trials,
except for the only Food and Drug Administration (FDA) approved recombinant tissue plasminogen
activator (tPA), which acts through vascular recanalization and tends to have numerous limitations,
of which, the transformation from ischemia to hemorrhage and narrow therapeutic window are
the most prominent ones [2]. The post-stroke pathological processes can be categorized into acute
(minutes to hours), subacute (hours to days), and chronic (days to months) phase [3,4]. The acute
phase is initiated by a robust release of reactive oxygen species (ROS) and pro-inflammatory mediators
immediately after the stroke onset, ultimately leading to the subacute and chronic phase, all contributing
to neurodegeneration [5,6]. The molecular mechanisms underlying ischemic stroke injury are quite
complex, primarily due to the involvement of numerous pathways that are associated with energy
metabolism, oxidative stress, excitatory amino acid toxicity, inflammation, free radicals formation,
calcium overload, and mitochondrial dysfunction, all of which lead to varying degrees of cellular
damage [7]. After a transient occlusion, irreversible events, starting from ionic imbalance to subsequent
membrane depolarization and calcium overload, are initiated, triggering oxidative stress and neuronal
cell death [8]. ROS, like free radicals damage lipids, proteins, DNA, and cause intracellular organelle
destruction via plasma and organelle membrane peroxidation [9]. Moreover, ROS production leads to
the activation of downstream inflammatory and apoptotic cascading pathways that are associated
with glia cells stimulation and the infiltration of granulocytes into the brain [9]. Numerous researches
suggest that neurons in the penumbral region undergo apoptosis several hours or days after ischemia
and could be rescued [10]. Thus, this region is salvageable and targeting this region to prevent apoptosis
seems to be a rational approach to limit cerebral infarct following clinical stroke.
Nrf2 (nuclear factor E2-related factor or nuclear factor erythroid 2 or p45-related factor 2) has
been extensively studied as a potential neuroprotective signaling pathway [11]. It is predominantly
associated with Kelch-like ECH-associated protein 1 (keap1) in the cytoplasm as an inactive dimer.
Keap1 suppresses Nrf2 activation and prevents its nuclear translocation. Upon exposure to stress
signal, the complex is dissociated and Nrf2 is set free for nuclear translocation, where it triggers the
innate antioxidant machinery of the cell. In the nucleus, Nrf2 binds to antioxidant response elements
(AREs) and triggers transcription machinery of endogenous protective enzymes, including antioxidant
genes, phase II detoxifying enzyme, anti-inflammatory genes, and molecular chaperones, and it further
induces several cellular protective functions in numerous inflammatory reactions, malignant tumors,
cardiovascular diseases, and respiratory diseases [12]. Hence, it might act as a prominent therapeutic
target in acute ischemic stroke, owing to its imperative role in cellular resistance to exogenous toxic
substances and oxidative stress.
All trans-retinoic acid (ATRA) is a vitamin-A derivative and binds to retinoic acid receptors (RARs)
and demonstrates immunoregulatory activities in numerous models [13]. Conflicting activities have
been attributed to ATRA, including some neuroprotective effects [14,15]. However, researchers have
also documented the inhibitory effects of ATRA on the Nrf2-ARE pathway, where it either
augmented Nrf2-Keap dimer in the cytoplasm or inhibited the activation of ARE [16,17]. In another
study, the inhibitory effects of ATRA were reported, owing to retinoic acid receptors (RAR),
ultimately inhibiting ARE driven genes [18]. It was employed as an Nrf2-inhibitor in the present study
owing to its Nrf2 inhibitory potential.
Oxadiazoles are five-membered heterocyclic compounds presenting diverse biological activities.
Previously, these agents have been extensively researched for various biological activities, including
anti-inflammatory and antioxidant potentials [19–21]. These oxadiazoles can be considered as
neuroinflammatory modulators owing to their high antioxidant potential. A novel 1,3,4 oxadiazole
derivative (N-{4-[(5-sulfanyl-1,3,4-oxadiazol-2yl) methoxy] phenyl} acetamide (named as A3) was
chosen based on its previously reported toxicity assessment, tumor inhibition, antioxidant, analgesic,
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2. Materials and Methods
2. Materials and Methods
2.1. Chemicals and Reagents
2.1. Chemicals and Reagents
Proteinase K and PBS tablets were obtained from MP Biomedicals (Irvine, CA, USA).
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2.2. Experimental Groups and Drug Treatment
2.2. Experimental Groups and Drug Treatment
In this study, adult male Sprague–Dawley rats weighing 230–260 g, 7–10 weeks were used,
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is the most stressful invasive procedure and in which limited mobility with severe suffering is an
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most stressful invasive procedure and in which limited mobility with severe suffering is an established
documented protocol, and our group was more interested in rats that survive this period. By this, we did
not euthanize any rats until 24 h of the ischemic period. We applied all of the laboratory procedures
to minimize rat sufferings, such as heating pad, sterilization, and fluid replenishment with normal
saline. The rats were randomly divided into six experimental groups (Figure 2). The sham-operated
control group (n = 17), vehicle-treated p-MCAO group (n = 17), A3 treated group both at low (5 mg/kg)
(n = 17), and high dose (n = 16) (10 mg/kg), ATRA treated group (n = 15) and A3 + ATRA treated group
(n = 15).

Figure 2. Schematic representation of the in vivo study design. Sham group: rats underwent surgery
without filament insertion, vehicle-treated-p-MCAO group: rats treated with vehicle after p-MCAO
induction, A3+p-MCAO (5 mg/kg) group: rats received 5 mg/kg of A3, 30 min after p-MCAO,
A3+p-MCAO (10 mg/kg) group: rats received 10 mg/kg of A3, 30 min after p-MCAO, ATRA+p-MCAO
(5 mg/kg) group: rats received 5 mg/kg of All trans-retinoic acid (ATRA) 30 min before p-MCAO,
A3+ATRA+p-MCAO group: rats received 5 mg/kg of ATRA 30 min before p-MCAO and 10 mg/kg of
A3 30 min after p-MCAO. Rats were sacrificed after 24 h of p-MCAO for further analysis.

A3 and ATRA were both dissolved in saline (containing 5% DMSO) and all rats received
a single intraperitoneal dose of either A3 (5 mg/kg or 10 mg/kg) or vehicle, 30 min after permanent
MCAO or ATRA (5 mg/kg) 30 min before MCAO occlusion. All of the animals were decapitated
24 h after permanent MCAO and brain tissues were collected. A total of seven animals died
during the experimental procedures, of which three were from the p-MCAO group, one from
high dose A3, two from low dose A3, and one from the sham group, which were further adjusted by
supplementing more animals. The reported reason for this mortality is edema formation, BBB leakage,
and hypothalamic shutdown [24]. The ethics committee is mostly aware of the mortality in experimental
setup, particularly in this model, as we constantly engaged them for our work.
2.3. Animal Preparation and MCAO Surgery
The animals were anesthetized with an I/P administration of a cocktail of xylazine (9 mg/kg)
and ketamine (91 mg/kg). The body core temperature was maintained while using a heating pad.
MCAO was carried out, as described previously [25–28]. Briefly, the right common carotid artery
(R-CCA) and its bifurcating branches; internal and external carotid arteries were exposed after a midline
cervical incision. Superior thyroid artery and the occipital artery, which are small protrusions from
the external carotid artery, were identified and knotted with a thin black (6/0) silk and eventually
ligated to allow free movement of the external carotid artery. The external common carotid artery
was then tied with silk (6/0) near the hyoid bone that was located above the ligated superior thyroid
artery and immediately incised near the bifurcating point. Throughout this procedure, extra care
was exercised in order to avoid excessive bleeding. For occlusion, a blue nylon filament (3/0) with
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a blunted round end was used, which was inserted through the opening of the external carotid artery
and pushed into the internal carotid artery up to 18–19 mm (depending upon the weight and age of the
rat) until the origin of the middle cerebral artery (MCA), where a light resistance to the advancement
of nylon indicated MCA occlusion. The nylon was then tied in place with the lumen of the external
carotid artery and the skin was then sealed. All of the animals were subjected to carbon dioxide
(CO2 ) euthanasia for tissue collection. The sham group underwent the whole procedure without nylon
insertion. The only shortcoming in this method was the absence of the Doppler effect and relative
blood flow measurement, though we constantly performed occlusion with suitable experimental skills.
The exclusion criteria included animals showing no depressed signs or alteration in movements after
awakening from anesthesia. No significant adverse effects were observed in drug-treated animals,
as pilot toxicity studies indicated a significantly greater dose.
2.4. Neurobehavioral Tests
The neurobehavioral analysis was conducted after 24 h of occlusion in order to assess sensory-motor
deficits. To ensure accuracy, tests were performed by an experienced, blinded observer. The Bederson
scale and 28-point neuro scores were run in parallel to validate behavioral deficits and neuronal damage.
2.4.1. Bederson Scale
The Bederson scale was assessed to test the neurological state of rats using previously published
protocols [29]. Parameters, such as forelimb flexion, circling behavior, and resistance to lateral push,
were assessed and grading was done on a scale of 0–3, with 0 representing no neurological deficit and
3 representing maximum neurological deficit.
2.4.2. 28-Point Neuro Score
28-point neuro score was used to estimate the extent of sensorimotor deficits based on previously
mentioned protocols [30]. Several tests were performed, including (i) circling, (ii) motility, (iii) general
physical condition, (iv) righting reflex; ability to turn itself when placed on its back, (v) paw placement
on the tabletop, (vi) its ability to climb itself up on a horizontal bar, (vii) ascending on an inclined
platform, (viii) grip-strength, (ix) contralateral reflex, (x) contralateral rotation where it rotates when
it is held by the base of its tail, and (xi) visual forepaw reaching. An aggregate score of 28 indicates
a healthy neurological function, whereas 0 indicates severe neurological deficits. All of the experiments
were performed following the SOPs that were approved by Stanford Behavioral and Functional
Neuroscience Laboratory.
2.5. Determination of Oxidative Stress Markers
Oxidative stress markers, such as the glutathione s-transferase (GST) activity and reduced
glutathione (GSH) levels, were determined to assess the degree of oxidative damage and the relative
effect of the test drug. The brain tissue samples were homogenized in 0.1 M sodium phosphate
buffer (PBS) (pH 7.4), which contained phenylmethylsulfonyl fluoride (PMSF) as a protease inhibitor,
centrifuged at 4000× g for 10 min at 4 ◦ C and supernatant was collected. GSH level was determined
using a previously reported method with slight modifications [31]. 0.6 mM DTNB was dissolved in 0.2 M
sodium phosphate, and 2 mL of this solution was mixed with 0.2 mL of the supernatant. Further, 0.2 M
phosphate buffer was added to this mixture, to make a final volume of 3 mL. The absorbance
of the reaction mixture was measured after 10 min at 412 nm while using a spectrophotometer.
Phosphate buffer was used as blank, whereas the DTNB solution was used as control. Real absorbance
was calculated by subtracting the absorbance of control from that of the tissue lysate. The final
GSH values were expressed in µmoles/mg of proteins. Likely, for the determination of GST activity,
the previously reported protocol was followed [32]. 5 mM GSH and 1 mM CDNB in 0.1 M phosphate
buffer solution were freshly prepared. Three replicates of 1.2 mL reaction mixture were placed in
a glass vial. Tissue supernatant (60 µL) was then added to the reaction mixture. Three blanks were also
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made while using 60 µL water instead of tissue lysate. Aliquots of 210 µL from the reaction mixture
were pipetted in a microtiter plate and the reaction rate was recorded at 340 nm for 5 min at 23 ◦ C using
ELISA microplate reader (BioTek ELx808, Winooski, VT, USA). The GST activity was calculated using
the extinction coefficient of the product formed and expressed as µmoles of CDNB conjugate/min/mg
of protein.
2.6. LPO Assay
Lipid peroxidation assay was carried out by measuring thiobarbituric acid reactive substances
(TBARS) using colorimetry, as described previously with slight modifications [33]. The assay mixture
consists of 580 µL of 0.1 M phosphate buffer (pH 7.4), 200 µL supernatant, 20 µL of ferric chloride,
200 µL of 100 mM ascorbic acid and incubated on a water bath at 37 ◦ C for 60 min. After one hour of
incubation, the reaction was stopped by adding 1000 µL of 10% trichloroacetic acid (TCA) and 1000 µL
of 0.66% thiobarbituric acid (TBA) to samples. The tubes were retained on the water bath for 20 min,
cooled on an ice bath, and finally centrifuged at 3000× g for 10 min. Supernatant’s absorbance and blank
(containing all reagents except test drug) were measured at 535 nm to determine the concentration of
TBARS-nM/min/mg protein.
2.7. NO Assay
Nitric oxide assay was performed according to reported protocols with slight modifications [34].
50 µL of tissue supernatant and 50 µL of normal saline were mixed with an equal volume of Griess
reagent containing 1% sulfanilamide in 0.1% naphthyl ethylenediamine dihydrochloride, and 5%
phosphoric acid in distilled water. The resultant reaction mixture was incubated at 37 ◦ C for 30 min.
The absorbance of the reaction mixture was detected at 546 nm while using ELISA microplate reader
(BioTek ELx808) using standard sodium nitrite solution in order to calibrate the absorbance coefficient.
2.8. Brain Water Content
Brain edema was quantitated using the previously described method [35]. Briefly, the animals were
decapitated under anesthesia and the brain was removed. The whole-brain was weighed immediately
on an electronic analytical balance to obtain the wet weight. The brain tissues were then dried at 120 ◦ C
for 6–8 h to obtain the dry weight. The formula used was as follows:
(Wet weight − Dry weight)/wet weight × 100
2.9. 2,3,4-Triphenyl Tetrazolium Chloride Staining
The rats were sacrificed under anesthesia, and brain tissue was collected. Three-millimeter slices
were made from the frontal lobe using a sharp blade. These were then incubated at 37 ◦ C for 20 min in
a freshly prepared TTC solution (2% in PBS), in a water bath until a clear white/red coloring demarcation
was observed. The slices were fixed using a 4% paraformaldehyde solution and then photographed for
percent infarct area determination. ImageJ software (ImageJ 1.3; https://imagej.nih.gov/ij/) was used
for infarct area determination and it was expressed as a percentage to the total area. To overcome the
false reading of brain edema, the corrected brain infarction was calculated using the formula:
Corrected infarct area = [left hemisphere area − (right hemisphere area − infarct area)]/100
These sections were then processed for paraffin blocks preparation using an embedding machine
and rotary microtome (n = 7/group).
2.10. Hematoxylin Eosin Staining
After de-paraffinizing tissue slides using absolute xylene (100%), it was followed by rehydrating
with absolute ethanol, gradient ethanolic concentrations (95% to 70%), and subsequently with distilled
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water. The slides were then rinsed with PBS and kept in hematoxylin for a total of 10 min. After due
time, the slides were placed for 5 min under running tap water in a glass jar. Slides were then probed
under the microscope for nuclear staining, and if staining was not clear, hematoxylin timing was
increased. The slides were then treated with 1% HCl and 1% ammonia water for a short interval and
immediately rinsed with water again. These were then immersed in an eosin solution for 5–10 min,
followed by rinsing with water and finally air-dried. Slides were then dehydrated using graded ethanol
(70%, 95%, and 100%), fixed in xylene and cover-slipped. The images were captured using an Olympus
light microscope (Olympus, Tokyo, Japan) and analyzed using ImageJ software. Five images per group
were captured and analyzed while focusing on neuronal shape, size, infiltrated cells, and vacuolation.
2.11. Immunohistochemical Analysis
Immunohistochemical analysis was performed, as described previously with minor
modifications [28,36,37]. The tissue slides were subjected to deparaffinization protocol, which started
from three different xylene treatments for 10 min. and then rehydrated in graded alcohol preparation
(commencing from 100% to 70%, each wash for 5–10 min). These slides were subsequently rinsed
with distilled water to clear ethanol remaining. The slides were processed for antigen retrieval with
proteinase K and washed with 0.1 M PBS. The peroxidase activity was quenched by applying a diluted
hydrogen peroxide solution (3% in methanol). After washing with 0.1 M PBS, slides were incubated
with 5% NGS (normal goat serum) containing 0.1% Triton X-100 for a minimum of 1 h in a humidified
chamber. After blocking, the slides were kept for overnight incubation at 4 ◦ C with primary antibodies
as anti-COX-2, anti-p-JNK, anti-TNF-α, anti-p-NF-κB, anti-Nrf2, anti-TLR4, anti-Iba-1, and anti-HO-1
(Dilution 1:100, Santa Cruz Biotechnology, Dallas, TX, USA). The next morning, after washing twice
with 0.1 M PBS, they were incubated for 90 min. with biotinylated secondary antibodies (dilution factor
1:50) in a humidified chamber. The slides were again washed and incubated for 1 h with ABC reagents
(Santa Cruz Biotechnology, USA) in a humidified chamber. Slides were then stained in DAB solution,
washed with distilled water, dehydrated in graded ethanol, fixed in xylene, and cover-slipped using
mounting medium. Immunohistochemical TIF (Tagged Image Format file) images of the slides were
taken using a light microscope (Olympus, Tokyo, Japan) taking three images per slide. The number
of immune-positive cells expressing p-JNK, TNF-α, p-NF-κB, COX-2, Nrf2, TLR4, Iba-1, and HO-1
in cortex/striatum/total area of the brain were counted through ImageJ software by first optimizing
the TIF image background according to the threshold intensity and then analyzing the intensity for
the number of immune-positive cells at the same threshold intensity for all groups. These were then
expressed in terms of the relative integrated density for the number of immune-positive cells of the
samples’ comparative to the sham.
2.12. Immunofluorescence Analysis
Immunofluorescence was performed, as described previously [28]. The slides were first deparaffinized
with xylene and rehydrated with a series of ethanol concentrations (100%, 90%, 80%, and 70%) followed
by washing with distilled water and PBS. Antigen retrieval was performed with protein kinase,
and it was washed with 0.01 M PBS, followed by 1 h incubation in blocking solution containing
0.3% Triton X-100 and 3% normal serum in 0.01 M PBS, according to the source of a secondary
antibody. After blocking, the slides were then incubated overnight at 4 ◦ C, with a primary antibody
against Nrf2 (1:100, Santa Cruz Biotechnology, Inc.). The next day, after PBS washing, the slides
were treated with fluorescent-labeled secondary antibody tetramethylrhodamine isothiocyanate
(TRITC, 1:50, Santa Cruz Biotechnology Inc.) for signal amplification, incubated for one hour in
a dark chamber at room temperature, and then cover-slipped using Ultra Cruz mounting medium
containing 40 ,6-diamidino-2-phenylindole (DAPI) (Santa Cruz Biotechnology, Inc.). The TIF Images
were then captured using a confocal scanning microscope (Flouview FV 1000, Olympus, Tokyo, Japan).
Three images per group were taken and the fluorescence intensity of the same regions of cortex/total
area of the TIF images for all groups was measured while using ImageJ software. The background of all
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the TIF images was optimized according to the threshold intensity and intensity of immunofluorescence
was also analyzed at the same threshold intensity for all groups and the results were expressed as the
relative density of sample relative to sham.
2.13. Enzyme-Linked Immunosorbent Assay (ELISA)
Rat Nrf2, p-NF-κB, HO-1, and TNF-α ELISA kits were used to quantify the expression of the
respective proteins. Expression was measured as per manufacturer’s instructions (Shanghai Yuchun
Biotechnology, Shanghai, China). An appropriate amount of tissues (50 mg) were first homogenized
while using Silent Crusher M (Heidolph) at 15,000 RPM in PBS (2500 µL) containing PMSF as protease
inhibitor and then centrifuged at 4000× g for 10 min and the supernatant was separated. The total
protein concentration in each group was determined by the BCA method (Elabscience), and the
equivalent quantity of protein was then loaded to determine the protein expression of Nrf2, p-NF-κB,
TNF-α, and HO-1 while using ELISA microplate reader (BioTek ELx808) and the concentration (pg/mL)
were then normalized to total protein content (pg/mg total protein).
2.14. Statistical Analysis
All of the data are presented as mean ± SEM. 2,3,4-triphenyl Tetrazolium Chloride Staining,
neurobehavior results, and oxidative stress data were analyzed using One-Way ANOVA, followed by
posthoc Bonferroni’s multiple comparison test using GraphPad Prism-8 software. For the rest of the
data, Two-Way ANOVA followed by posthoc Bonferroni’s Multiple Comparison test was performed.
ImageJ software (ImageJ 1.30; https://imagej.nih.gov/ij/) was used to analyze the morphological data.
Symbols # or * represents significant difference values p < 0.05, ## or ** represent p < 0.01 and ### or ***
represents p < 0.001 values for significant differences. Symbols * and # shows significant difference
relative to sham and p-MCAO, respectively.
3. Results
3.1. Effects of Post-Treatment Dosage Regimen on Brain Infarction and Neuronal Cell Loss
The neuroprotective effect of A3 on acute neurological deficits was demonstrated first.
The neurological score was assessed after 24 h of permanent stroke while using the Bederson
Scale and 28-point neuro score. Animals that were subjected to p-MCAO (n = 7/group) exhibited
severe neurological deficits (score 3 by Bederson scale) and a score of 11–15 (28-point composite score),
which demonstrated an impaired cortical and striatal functions with associated diminished motor
and sensory coordination (p < 0.001, Figure 3A,B). Treatment with A3 attenuated the neurobehavior
deficits in a dose-dependent manner (p < 0.05, p < 0.01, Figure 3A,B). The 10 mg/kg dose exhibited
a relatively better neuroprotective effect (p < 0.01, Figure 3A,B). Animals that were subjected to
p-MCAO also revealed an increased water content (Figure 3C, p < 0.05, n = 5/group) compared to sham,
depicting edema formation following ischemic stroke. A3 treatment mitigated the increased brain water
content to a significant level (Figure 3C, p < 0.05). The focal cerebral ischemic model predominantly
impairs the neocortex and striatal region, as previously demonstrated [38]. Therefore, TTC staining
was performed in order to assess the cellular viability and neuronal damage (Figure 3D). As shown,
A3 treatment reduced infarct area in a dose-dependent manner with 10 mg/kg showing maximum
reduction of infarction (p < 0.001, One-way ANOVA followed by Bonferroni’s multiple comparisons
test, n = 7/group) as compared to 5 mg/kg, with corrected infarct areas of 5.74% and 14.73%, respectively,
as compared to 36.75% for p-MCAO (Figure 3D).
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Figure 3. Effect of post-treatment dosage regimen of A3 on brain infarction and neuronal cell loss.
(A) 28 points neuro scoring. *** p < 0.001 vs. sham, while ## p < 0.01 and # p < 0.05 vs. p-MCAO
group (B) Bederson scale. A3+p-MCAO rats showed significantly reduced neurological deficits with
a higher dose of A3 (## p < 0.01) as compared to p-MCAO rats (n = 7/group). *** p < 0.001 vs. sham,
while ## p < 0.01 and # p < 0.05 vs. p-MCAO group (C) Brain water content. p-MCAO showed
significant % water content/edema formation, mitigated by A3 post-treatment (# p < 0.05, n = 5/group).
* p < 0.05 vs. sham, while # p < 0.05 vs. p-MCAO group (D) % Infarct area was quantified by TTC
staining started from the frontal cortex to the occipital cortex, which differentiates between ischemic
and non-ischemic areas (n = 7/group). *** p < 0.001 vs. sham, while ## p < 0.01 vs. p-MCAO group.

3.2. Effects of ATRA on A3 Mediated Neuroprotection
The activation of Nrf2 was inhibited by ATRA to demonstrate the possible role of Nrf2 in
A3-mediated neuroprotection [16–18]. A dose of 5 mg/kg of ATRA resulted in aggravated oxidative
stress markers as shown in Table 1. Further validation of these results was demonstrated through
the neuro score (Figure 4A,B, n = 7/group) and corrected infarct area (Figure 4C, n = 7/group).
ATRA abolished the protective effects of A3, causing intense neurobehavioral deficits, brain edema
together with infarct area (Figure 4A–C, One-way ANOVA with Bonferroni’s multiple comparisons
test, n = 7/group). These morphological changes were probed in the peri-infarct frontal cortex and
striatum (Figure 4E), which was further investigated by Hematoxylin Eosin Staining (H & E).
Atypical features were observed in the ipsilateral cortex and striatum, such as changes in neuronal shape
and size (angular, swollen, and scalloped morphology), in staining (pyknosis/cytoplasmic eosinophilia,
nuclear basophilia), and vacuolation (p < 0.001, Figure 4F, n = 5/group). These neurological damages
were attenuated by A3 treatment as evidenced by an increase in the total number of intact neurons.
Further to demonstrate glial cell activation after these infiltrations, we observed the immunoreactivity
of Iba-1 as microglia cells (Figure 4G). Likely, higher Iba-1 positive cells were noticed in the frontal
cortex of ischemic operated animals (p < 0.001). Moreover, ATRA exaggerated the deleterious effects of
MCAO and diminished the neuroprotective effects of A3, thus impeding the Nrf2 and implicating its
explicit involvement in the neuroprotective role of A3 (p < 0.05, n = 5/group).

Biomolecules 2020, 10, 816

10 of 19

Figure 4. Effects of ATRA on A3 mediated neuroprotection. (A) 28 points composite scoring.
(B) Bederson scale. ATRA+p-MCAO rats exhibited severe neurological impairment as with p-MCAO
(n = 7/group). (C) The brain water content of the cerebral hemisphere in the ischemic side in each
group (n = 5/group). ** p < 0.01 vs. sham group. ATRA+p-MCAO showed no significant changes in %
water content/edema formation as compared to p-MCAO. (D) % Infarct area was quantified by TTC
staining started from the frontal cortex to the occipital cortex, which differentiates between ischemic
and non-ischemic areas (n = 7/group). (E) Coronal sections indicating frontal cortex (1), parietal cortex
and insular cortex (2), and the piriform cortex (3). The analyzed region of interests indicated by 1 and
F. (F) Representative images of hematoxylin and eosin staining in various groups. Scale bar = 70 µm.
magnification 40×. (G) Representative images of Iba-1 immunostaining in the cortex. Scale bar = 70 µm,
magnification 40×. The thin arrows indicated normal neuronal cells while the arrowhead indicates
microglial phenotype. *** p < 0.001 vs. sham, # p < 0.05 and ## p < 0.01 vs. p-MCAO group.

3.3. Effect of A3 on Nrf2 Signaling Pathway
Furthermore, we antagonized the Nrf2 effects by ATRA using a dose of 5 mg/kg to investigate
whether A3 effects are Nrf2-dependent. The neuroprotective effect of A3 was abolished by ATRA
administration, as shown by ELISA analysis (Figure 5A). We performed immunohistochemistry
and immunofluorescence, to further validate the transition of Nrf2 localization between cytoplasm
and nucleus (Figure 5B,C). The results showed that A3 promoted the nuclear localization of Nrf2,
as shown by DAPI/TRITC co-expression, whereas ATRA abrogated this transition, as demonstrated
by immunohistochemical analysis. Furthermore, we also determined the protein expression of HO-1,
which is downstream of the Nrf2 pathway, and a similar pattern of expression was observed for ATRA
and A3 treated groups (Figure 5D,E). These results demonstrated that A3 could modulate both Nrf2
and HO-1 expression, while ATRA attenuated the effects of A3 on Nrf2.
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Figure 5. A3 modulates the antioxidant capacity of the brain via the Nrf2 signaling pathway (A)
The protein expression of Nrf2 was quantified by ELISA in the brain cortex. ** p < 0.01 vs. sham while
# p < 0.05 vs. p-MCAO (B) Immunohistochemical results for Nrf2 in cortex and striatum tissues of the
brain. Bold arrows indicate a clear nucleus, while thin arrowhead shows nuclear staining, indicating Nrf2
translocation to the nucleus. Sham group shows the cytoplasmic localization of Nrf2 protein whereas
A3 + p-MCAO treated group demonstrated nuclear localization. Scale bar = 70 µm, magnification 40×,
(n = 5/group). * p < 0.05 vs. sham, # p < 0.05 vs. p-MCAO group. (C) Immunofluorescence reactivity of
Nrf2 in cortex (n = 5/group). The aforementioned data is the representation of 3 numbers of experiments.
Scale bar = 100 µm, magnification 40×. ** p < 0.01 vs. sham, # p < 0.05 vs. p-MCAO. Nrf2 was tagged by
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the TRITC signal, while the nucleus by DAPI. A3 increased the co-localization of DAPI and TRITC.
(D) The protein expression of HO-1, as quantified by ELISA in the cortex. ** p < 0.01 vs. sham,
## p < 0.01 vs. p-MCAO (E) Immunohistochemistry results for HO-1 in cortex and striatum tissues
of the brain. Scale bar = 50 µm, magnification 40×, (n = 5/group). *** p < 0.001 vs. sham, # p < 0.05
vs. p-MCAO group.

3.4. A3 Attenuated Oxidative Stress Induced by MCAO
Table 1 summarizes the alterations in antioxidative enzymes following p-MCAO, A3, and ATRA
treatment. p-MCAO induced ROS generation as opposed to sham, which is associated with nitric oxide
(NO) amassing (13.35 ± 2.48 µmoles/mg) and the depletion of GST activity (13.51 ± 0.75 µmoles CDNB
conjugate/min/mg of protein) and GSH level (14.28 ± 0.48 µmoles/mg of protein) in the cortex (p < 0.001).
A3 post-treatment at different doses attenuated the downregulation of GSH (40 ± 1.23 µmoles/mg of
protein) and GST (26.04 ± 2.11 µmoles CDNB conjugate/min/mg of protein) and reduced the level of
NO (5.63 ± 0.92 µmoles/mg) when compared to the p-MCAO group.
Table 1. Effect of A3 on oxidative enzymes.

Sham
p-MCAO
A3+p-MCAO (10mg/kg)
ATRA+p-MCAO
A3+ATRA+p-MCAO

NO
(µmoles/mg)

GST (µmoles CDNB
Conjugate/min/mg of Protein)

GSH (µmoles/mg
of Protein)

LPO (TBARS-nM/min/mg
Protein)

4.089 ± 1.84
13.35 ± 2.48 **
5.63 ± 0.92 ##
17.84 ± 1.2
15.45 ± 0.69

40.36 ± 1.09
13.51 ± 0.75 ***
26.04 ± 2.11 ###
14.9 ± 1.83
13.14 ± 2.06

83.4 ± 0.48
14.28 ± 0.48 ***
40 ± 1.23 ###
20 ± 1.97
18.4 ± 1.24

41.5 ± 0.42
118.8 ± 0.73 ***
64.3 ± 0.52 ###
111.3 ± 0.52 ##
113 ± 0.42 ##

Symbols *** or ### indicates significant difference at p < 0.001, while ** and ## indicates significant difference at
p < 0.01, respectively. *** vs. sham, # vs. p-MCAO group. The data are presented as mean ± SEM, with n = 5/group.
The symbol * shows a significant difference vs. sham and # shows the significant difference vs. p-MCAO.
Abbreviations: NO, nitric oxide; GST, glutathione S-transferase; GSH, reduced glutathione; LPO, lipid peroxidation;
TBARS, thiobarbituric acid reactive substances.

3.5. Effect of A3 on LPO
The results of the TBARS test indicated a drastic rise in peroxides in MCAO, which could be
restored by different doses of A3. The LPO concentration in the cortical homogenate was augmented to
(118.8 ± 0.73 nM/min/mg protein) in comparison to the sham group (p < 0.001, Table 1). A3 at 10 mg/kg
dose significantly (p < 0.001, Table 1) attenuated this rise (64.3 ± 0.52 nM/min/mg protein), an outcome
that could be comparable to the sham group.
3.6. A3 Attenuated p-MCAO Induced Inflammatory Mediators in the Brain
In order to detect the possible involvement of TNF-α and JNK, ELISA analysis was performed
and the results revealed the increased release of TNF-α in the p-MCAO group (p < 0.001) (Figure 6A),
whereas A3 treatment significantly reduced the protein hyperexpression (p < 0.01, Figure 6A).
Furthermore, the protein expression of TNF-α and p-JNK was validated by immunohistochemistry
analysis (Figure 6B,C).
3.7. A3 Enhances the Anti-Inflammatory Capacity via the Nrf2 Signaling Pathway
A30 s antioxidative effect was further extrapolated to its anti-inflammatory role. We noticed
comparatively elevated protein expression of TLR4 in the p-MCAO group as numerous reports
have established the involvement of TLR4 in inflammation, which is eventually associated with the
downstream inflammatory targets as p-NF-κB, and COX-2 [39,40], as shown in Figure 7A (p < 0.001).
Additionally, p-NF-κB and COX-2 expression were also analyzed, and the results indicated that both
are overly expressed in the p-MCAO group (p < 0.001, Figure 7B–D). A3 (10 mg/kg) mitigated both
p-NF-κB and COX-2 expression along with TLR4.
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Figure 6. A3 ameliorated p-MCAO-induced neuroinflammation. (A) The release of TNF-α was
quantified by ELISA in the cortex. *** p < 0.001 vs. sham, ## p < 0.01 vs. p-MCAO (n = 5/group).
(B) Immunohistochemical results for TNF-α in cortex and striatum tissues of the brain.
Scale bar = 70 µm, magnification 40× (n = 5/group). TNF-α exhibited cytoplasmic localization in
both examined brain areas. (C) Immunohistochemistry results for p-JNK in cortex and striatum
tissues of the brain. Scale bar = 70 µm, magnification 40×, (n = 5/group). p-JNK exhibited cytoplasmic
localization. *** p < 0.001 vs. sham, # p < 0.05 or ## p < 0.01 vs. p-MCAO group. The bold arrow
indicates no expression while thin arrow indicates cytoplasmic localization of TNF-α and p-JNK.

Figure 7. Effect of A3 on outcomes of p-MCAO induced inflammatory mediators. (A) Immunohistochemistry
images of TLR4 in cortical and striatal tissues of the brain. Scale bar = 70 µm, magnification 40×,
(n = 5/group). (B) Quantification of p-NF-κB expression by ELISA in the cortex. *** p < 0.001 vs. sham,
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# p < 0.05 vs. p-MCAO (C) Immunohistochemistry results for p-NF-κB in cortex and striatum tissues
of the brain. Scale bar = 70 µm, magnification 40×, (n = 5/group). (D) Immunohistochemistry data
for COX-2 in the cortex and striatum tissues of the brain. Scale Bar = 70 µm, magnification 40×,
(n = 5/group). p-NF-κB exhibited nucleus localization while COX-2 and TLR4 manifested cytoplasmic
localization in both tissues of the brain. *** p < 0.001 vs. sham, # p < 0.05 and ## p < 0.01 vs. p-MCAO
group. The bold arrow indicates no expression while thin arrow indicates cytoplasmic localization
of TLR4 and COX2. For p-NF-κB, the bold arrow indicates no nuclear expression while arrowhead
indicates nuclear localization.

4. Discussion
The present study was carried out in order to explore the neuroprotective effects of A3 in
ischemic stroke-induced neurodegeneration. We demonstrated that A3 can mediate neuroprotective
effects possibly by mitigating neuroinflammation, augmenting free-radical scavenging, and eventually
reducing oxidative stress. We likely demonstrated aggravation of stroke due to wearing off the
A3 mediated neuroprotective actions by employing an Nrf2 pathway inhibitor, ATRA. Moreover,
A3 downregulated the expression of pro-inflammatory cytokines that are associated with enhanced
endogenous anti-oxidants (Figure 8).
In humans, ischemic stroke occurs most commonly in part of the brain perfused by the middle
cerebral artery MCA. Induced by intraluminal suture, focal cerebral ischemia is a well-established animal
stroke model of clinical relevance, comprising of transient (t-MCAO) and permanent (p-MCAO) [41].
Previous studies have provided substantial research information to our current understanding
regarding the pathophysiology of ischemic stroke [7,42]. Immediately after stroke onset, free radicals
are released, which mobilizes the endogenous antioxidative machinery, of which, superoxide dismutase
(SOD), glutathione s-transferase (GST), and reduced glutathione (GSH) are the first-line defense
antioxidants [43]. Our results indicated that the post-ischemic A3 administration attenuated the
LPO [44] and raised the depleted GST and GSH levels. GST and GSH have been extensively explored
as having detoxifying effects against oxidative stress and they are pivotal to sustaining cellular
homeostasis and scavenging free radicals [43,45]. Thus, sustaining the level of GST, GSH, along with
low lipid peroxidation, might account for the antioxidant nature of A3.

Figure 8. The graphical representation to elaborate on the possible mechanism underlying antioxidative
and anti-inflammatory potential of A3 against the p-MCAO-induced brain injury. A3 causes Nrf2
activation and suppresses oxidative damage as indicated by elevated GST and GSH and reduced NO
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eventually leading to neuroprotection. ATRA blocks Nrf2 activation thereby leading to inhibition
of endogenous antioxidative capacity. The majority of ROS and RNS are the products of oxygen
metabolism in mitochondria. The superoxide anion produced is exported to the cytosol, and in the
attempt to reduce the toxicity, some more reactive species are generated. These reactive species then
cause degradation of DNA, lipids, and proteins. Under such conditions, the antioxidant response
system (ARS) becomes activated to balance redox status. In our body, Nrf2 acts as a master regulator
and is activated in response to stress via two mechanisms; a kinase-independent mechanism where
reactive specie directly oxidize or nitrosylate the keap 1, a cysteine-rich protein that is bound to Nrf2 and
thus releasing Nrf2. The other mechanism is kinase-dependent degradation, where a stressor such as
glutamate, through activation of the Gq pathway, phosphorylate Nrf2. As a result, Nrf2 is transported
into the nucleus where it displaces Bach1, a transcriptional repressor of ARE (antioxidant response
elements), and heterodimerize with Maf and bind to ARE on DNA, eventually triggering transcriptional
factors for NQO1, HO-1, and GST, thus increasing cellular defense against redox-modulators.

As a part of endogenous antioxidant machinery, Nrf2 plays a pivotal role in redox
homeostasis and regulates the transcription of antioxidant enzymes [18]. Following oxidative
insult, including MCAO, Nrf2 translocates from the cytoplasm to the nucleus and activates
transcription of several downstream antioxidant genes HO-1, NADPH quinone dehydrogenase-1
(NQO1), thioredoxin (TRX), GSH, SOD, and eventually protecting the cell from inflammation and
apoptosis [46–50]. Several studies demonstrated the antioxidant and free radical scavenging effects of
Nrf2 [51,52]. Conversely, Nrf2-deficient animals are remarkably more susceptible to brain insult and
neurological damage than WT mice [53]. Our findings demonstrated the translocation of Nrf2 from
the cytoplasm to the nucleus in the MCAO group in response to the oxidative stress signals, as the
body’s natural defense mechanism. However, a further upregulation of Nrf2 levels was observed
upon A3 treatment, associated with higher expression of downstream HO-1, demonstrating the
antioxidant potential of A3. These effects, though, were subsided with Nrf2 inhibitor ATRA,
indicates the possible role of Nrf2 in the A3 mediated neuroprotection. ATRA inhibits Nrf2 by
several mechanisms: First, by augmenting the Nrf2-Keap1 dimer in the cytoplasm, which previously
exaggerated intracerebral hemorrhage [17]. Second, ATRA could inhibit the binding of Nrf2 with
ARE [16]. Third, the inhibitory effects of ATRA were attributed to its affinity for retinoic acid receptors
(RAR-ά, -β, -γ) [16,18], thereby inhibiting the expression of ARE driven HO-1, and NQO1 activation.
Based on these findings, we performed a series of experiments with different concentrations of ATRA
(data not shown) and optimized a dose of 5 mg/kg, 30 min pre-surgery, which exerted maximal Nrf2
inhibition, thus aggravating outcomes of ischemic brain damage. Moreover, how A3 effects Nrf2
translocation needs further investigation.
A strong relationship between inflammation and oxidative stress has been revealed in both neuronal
and non-neuronal models [54,55]. Furthermore, the activation of microglia, as indicated by Iba-1,
further enhances the inflammatory process inducing neuronal death by numerous mechanisms [56].
Various studies reported that ligands of toll-like receptors (TLR4) trigger activation of certain
stress-related kinases, including c-June N-terminal Kinases (JNK), which leads to the activation
of the mitochondrial apoptotic pathway [57]. JNK (p-JNK) is involved not only in apoptotic mediated
signaling, but also implicated in immune responses due to cross-talk with various proinflammatory
cytokines [58]. Consistent with previous studies, we found an increased TLR4 and JNK expression,
which was mitigated by A3 treatment, suggesting the anti-inflammatory role of A3.
Substantial evidence suggests the release of several pro-inflammatory cytokines, such as
interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrotic factor-α (TNF-α) from glial cells [54,59].
Many transcription factors, including interferon regulatory factor-1 (IFN-1), NF-κB, and early
growth response-1 factor (EGR1), also stimulate pro-inflammatory gene expression. which, in turn,
leads to secondary neuronal apoptosis. Our study findings are similar to the previous reports,
whereby inflammatory cytokines (TNF- α) are released from glial cells, starting a vicious cycle of
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activating other mediators of inflammation, such as p-NF-κB, COX-2, and iNOS during an early phase
of ischemic insult, and that are attenuated by A3 administration.
5. Conclusions
In conclusion, our in-vivo findings demonstrate that A3 promotes neuronal survival by activating
endogenous antioxidant Nrf2. Moreover, A3 also attenuated p-MCAO induced inflammatory cascade
by the possible modulation of the Nrf2 pathway, which eventually accounts for its neuroprotective
effects against neuronal inflammation. However, extensive exploration is still required in order to
delineate the underlying protective mechanisms of A3.
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